A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Summary

The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC). The name of the study drugs involved in this research study is: * Sasanlimab (a type of monoclonal antibody) * Palbociclib (a type of kinase inhibitor) * Axitinib (a type of Vascular endothelial growth factor inhibitor)

Timeline

Start

2025-11-24

Primary completion

2026-10-01

Completion

2028-02-01

Drugs

Indications